Cargando…

Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy

Background: The aim of this study is to evaluate the long-term therapeutic gain of induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiotherapy (IMRT). Methods: Data on 957 patients with stage T1-2N2-3 or T3-4N1-3 NPC treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Hao, Chen, Lei, Zhang, Jian, Li, Wen-Fei, Mao, Yan-Ping, Zhang, Yuan, Liu, Li-Zhi, Tian, Li, Lin, Ai-Hua, Sun, Ying, Ma, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332887/
https://www.ncbi.nlm.nih.gov/pubmed/28261337
http://dx.doi.org/10.7150/jca.16732
_version_ 1782511614246780928
author Peng, Hao
Chen, Lei
Zhang, Jian
Li, Wen-Fei
Mao, Yan-Ping
Zhang, Yuan
Liu, Li-Zhi
Tian, Li
Lin, Ai-Hua
Sun, Ying
Ma, Jun
author_facet Peng, Hao
Chen, Lei
Zhang, Jian
Li, Wen-Fei
Mao, Yan-Ping
Zhang, Yuan
Liu, Li-Zhi
Tian, Li
Lin, Ai-Hua
Sun, Ying
Ma, Jun
author_sort Peng, Hao
collection PubMed
description Background: The aim of this study is to evaluate the long-term therapeutic gain of induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiotherapy (IMRT). Methods: Data on 957 patients with stage T1-2N2-3 or T3-4N1-3 NPC treated with IMRT were retrospectively reviewed. Propensity score matching (PSM) method was adopted to balance influence of various covariates. Patient survival between IC and non-IC groups were compared. Results: For the 318 pairs selected from the original 957 patients by PSM, the median follow-up duration was 57.13 months (range, 1.27-78.1 months). The 5-year overall survival (OS), distant metastasis-free survival (DMFS), disease-free survival (DFS) and locoregional relapse-free survival (LRRFS) rates for IC group vs. non-IC group were 87.2% vs. 80.8% (P = 0.023), 88.1% vs. 83.2% (P = 0.071), 80.7% vs. 71.4% (P = 0.011) and 92.1% vs. 86.7% (P = 0.081), respectively. Multivariate analysis identify IC as an independent prognostic factor for OS (HR, 0.595; 95% CI, 0.397-0.891; P = 0.012) and DFS (HR, 0.627; 95% CI, 0.451-0.872; P = 0.006). After excluding the patients not receiving concurrent chemotherapy, IC was found to be an independent prognostic factor for OS (HR, 0.566; 95% CI, 0.368-0.872; P = 0.01), DMFS (HR, 0.580; 95% CI, 0.367-0.916; P = 0.02) and DFS (HR, 0.633; 95% CI, 0.444-0.903; P = 0.012). Conclusions: IC is an effective treatment modality for patients with stage T1-2N2-3 and T3-4N1-3 NPC, and the incorporation of IC with standard CCRT could achieve the best therapeutic gain.
format Online
Article
Text
id pubmed-5332887
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-53328872017-03-03 Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy Peng, Hao Chen, Lei Zhang, Jian Li, Wen-Fei Mao, Yan-Ping Zhang, Yuan Liu, Li-Zhi Tian, Li Lin, Ai-Hua Sun, Ying Ma, Jun J Cancer Research Paper Background: The aim of this study is to evaluate the long-term therapeutic gain of induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiotherapy (IMRT). Methods: Data on 957 patients with stage T1-2N2-3 or T3-4N1-3 NPC treated with IMRT were retrospectively reviewed. Propensity score matching (PSM) method was adopted to balance influence of various covariates. Patient survival between IC and non-IC groups were compared. Results: For the 318 pairs selected from the original 957 patients by PSM, the median follow-up duration was 57.13 months (range, 1.27-78.1 months). The 5-year overall survival (OS), distant metastasis-free survival (DMFS), disease-free survival (DFS) and locoregional relapse-free survival (LRRFS) rates for IC group vs. non-IC group were 87.2% vs. 80.8% (P = 0.023), 88.1% vs. 83.2% (P = 0.071), 80.7% vs. 71.4% (P = 0.011) and 92.1% vs. 86.7% (P = 0.081), respectively. Multivariate analysis identify IC as an independent prognostic factor for OS (HR, 0.595; 95% CI, 0.397-0.891; P = 0.012) and DFS (HR, 0.627; 95% CI, 0.451-0.872; P = 0.006). After excluding the patients not receiving concurrent chemotherapy, IC was found to be an independent prognostic factor for OS (HR, 0.566; 95% CI, 0.368-0.872; P = 0.01), DMFS (HR, 0.580; 95% CI, 0.367-0.916; P = 0.02) and DFS (HR, 0.633; 95% CI, 0.444-0.903; P = 0.012). Conclusions: IC is an effective treatment modality for patients with stage T1-2N2-3 and T3-4N1-3 NPC, and the incorporation of IC with standard CCRT could achieve the best therapeutic gain. Ivyspring International Publisher 2017-02-10 /pmc/articles/PMC5332887/ /pubmed/28261337 http://dx.doi.org/10.7150/jca.16732 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Peng, Hao
Chen, Lei
Zhang, Jian
Li, Wen-Fei
Mao, Yan-Ping
Zhang, Yuan
Liu, Li-Zhi
Tian, Li
Lin, Ai-Hua
Sun, Ying
Ma, Jun
Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy
title Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy
title_full Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy
title_fullStr Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy
title_full_unstemmed Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy
title_short Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy
title_sort induction chemotherapy improved long-term outcomes of patients with locoregionally advanced nasopharyngeal carcinoma: a propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiotherapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332887/
https://www.ncbi.nlm.nih.gov/pubmed/28261337
http://dx.doi.org/10.7150/jca.16732
work_keys_str_mv AT penghao inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy
AT chenlei inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy
AT zhangjian inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy
AT liwenfei inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy
AT maoyanping inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy
AT zhangyuan inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy
AT liulizhi inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy
AT tianli inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy
AT linaihua inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy
AT sunying inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy
AT majun inductionchemotherapyimprovedlongtermoutcomesofpatientswithlocoregionallyadvancednasopharyngealcarcinomaapropensitymatchedanalysisof5yearsurvivaloutcomesintheeraofintensitymodulatedradiotherapy